Drug Profile

Ibuprofen - PLx Pharma

Alternative Names: IBU-PC; Ibuprofen-PC; Ibuprofen-phosphatidylcholine; PL 1100; Zavryl

Latest Information Update: 18 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator
Developer PLx Pharma
Class Amines; Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
Mechanism of Action Cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Inflammation; Pain

Most Recent Events

12 Apr 2023 Greenwood Brands acquires all the assets of PLx Pharma
17 Jun 2021 Phase II development for Pain and inflammation is still ongoing in USA (PO) (PLx Pharma's pipeline, June 2021)
15 Jun 2018 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com